As of Jan 18
| +0.10 / +0.67%|
The 11 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 20.00 and a low estimate of 6.00. The median estimate represents a -7.28% decrease from the last price of 15.10.
The current consensus among 11 polled investment analysts is to Buy stock in Momenta Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.